Results 141 to 150 of about 36,146 (282)
Background: Age-related macular degeneration (AMD) is the leading cause of vision loss in elderly people. Current pharmacological treatment in vascular AMD includes anti-VEGF agents, such as ranibizumab and aflibercept. Additionally, the off-label use of
João Estarreja +4 more
doaj +1 more source
Impact of COVID-19 on a real-world treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration [PDF]
Keean Nanji +7 more
openalex +1 more source
Effects of photodynamic therapy on subfoveal blood flow in neovascular age-related macular degeneration patients [PDF]
V. Vinh Moreau-Gaudry +5 more
openalex +1 more source
Safety and tolerability of intravitreal umedaptanib pegol (anti-FGF2) for neovascular age-related macular degeneration (nAMD): a phase 1, open-label study [PDF]
Daniel S. Pereira +6 more
openalex +1 more source
Ocular syphilis masquerading as refractory retinal diseases
Purpose To report two cases of syphilis masquerading as chronic refractory macular diseases. Case descriptions Two patients had been diagnosed with neovascular age-related macular degeneration (neovascular AMD) and diabetic macular edema (DME ...
Sung Who Park +5 more
doaj +1 more source
Comprehensive Analysis of CRP, CFH Y402H and Environmental Risk Factors on Risk of Neovascular Age-Related Macular Degeneration [PDF]
Purpose: To examine if the gene encoding C-reactive protein (CRP), a biomarker of inflammation, confers risk for neovascular age-related macular degeneration (AMD) in the presence of other modifiers of inflammation, including body mass index (BMI ...
Adams, Scott +10 more
core
The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF [PDF]
Fang-Yuan Han +5 more
openalex +1 more source

